1. Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF Registry
- Author
-
Susano Lara-Vaca, Miguel E. Beltrán-Gámez, Pedro J. del Rivero Morfin, Reynaldo Magaña-Magaña, Alberto Z. Baños-Velasco, Carlos Cantú-Brito, Manuel Odín de los Ríos Ibarra, Jorge A. Vázquez-Acosta, Nicolás Reyes-Reyes, Ulises Rojel-Martínez, Marcelo Jiménez-Cruz, Lidia E. Betancourt-Hernández, Rocío Camacho-Casillas, Marco Alcocer-Gamba, Milton E Guevara-Valdivia, Julio A. Aguilar-Linares, Marco A. Islava-Gálvez, Norberto Matadamas-Hernández, J. Antonio González-Hermosillo, Manuel Alfonso Baños-González, Humberto Rodríguez-Reyes, and Manlio F. Márquez
- Subjects
embolic risk ,Male ,lcsh:Diseases of the circulatory (Cardiovascular) system ,medicine.medical_specialty ,Epidemiology ,medicine.drug_class ,direct oral anticoagulant ,030204 cardiovascular system & hematology ,antithrombotic treatment ,Middle income country ,03 medical and health sciences ,Antithrombotic treatment ,0302 clinical medicine ,Risk groups ,Fibrinolytic Agents ,Age groups ,Risk Factors ,vitamin k antagonist ,Thromboembolism ,Internal medicine ,Atrial Fibrillation ,medicine ,Humans ,In patient ,Registries ,030212 general & internal medicine ,Mexico ,Original Research ,Aged ,Community and Home Care ,anticoagulation therapy ,business.industry ,lcsh:Public aspects of medicine ,Incidence ,Age Factors ,lcsh:RA1-1270 ,Atrial fibrillation ,Vitamin K antagonist ,medicine.disease ,Stroke ,Survival Rate ,Clinical trial ,lcsh:RC666-701 ,cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business ,vitamin K antagonist - Abstract
Background: Documenting the patterns of oral anticoagulation therapy (OAT) is essential to prevent thromboembolic complications of nonvalvular atrial fibrillation (NVAF). Objective: To report the patterns of OAT according to age and thromboembolic risk in patients included in CARMEN-AF, a nationwide registry of NVAF in Mexico, an upper middle-income country. Material and methods: There were 1,423 consecutive patients ≥18 years old and with at least one thromboembolic risk factor enrolled in the CARMEN-AF Registry at their regular clinical visit during a three-year period. They were analyzed according to 1) age, 2) AF type, and 3) CHA2DS2-VASc score. Results: Overall, 16.4% of patients did not receive antithrombotic treatment, 19.4% received antiplatelet drugs (APD), 29.2% vitamin K antagonists (VKA), and 34.6% direct oral anticoagulants (DOAC). With increasing age, the proportion of subjects treated with VKA decreased significantly from 36.2% in subjects
- Published
- 2020
- Full Text
- View/download PDF